Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
18
SOLTF Quote, Financials, Valuation and Earnings
Last price:
$6.16
Seasonality move
:
16.5%
Day range:
$6.16 - $6.16
52-week range:
$6.16 - $13.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.79x
P/B ratio:
1.17x
Volume:
50
Avg. volume:
147
1-year change:
-37.3%
Market cap:
$553.6M
Revenue:
$91M
EPS (TTM):
-$0.27
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SOLTF
Nxera Pharma
|
-- | -- | -- | -- | -- |
|
AMGXF
AnGes
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream
|
-- | -- | -- | -- | -- |
|
SNBIF
SanBio
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical
|
$7.2B | -- | 0.1% | -- | $16.03 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SOLTF
Nxera Pharma
|
$6.16 | -- | $553.6M | -- | $0.00 | 0% | 2.79x |
|
AMGXF
AnGes
|
$0.36 | -- | $86.6M | -- | $0.00 | 0% | 22.98x |
|
HLOSF
Healios KK
|
$1.35 | -- | $121.7M | -- | $0.00 | 0% | 32.00x |
|
PPTDF
PeptiDream
|
$17.15 | -- | $2.2B | 20.38x | $0.00 | 0% | 7.14x |
|
SNBIF
SanBio
|
$5.81 | -- | $412.1M | -- | $0.00 | 0% | 97.52x |
|
TAK
Takeda Pharmaceutical
|
$13.10 | $16.03 | $41.5B | 21.67x | $0.33 | 4.72% | 1.38x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SOLTF
Nxera Pharma
|
48.92% | 1.984 | 55.24% | 3.73x |
|
AMGXF
AnGes
|
-- | 2.635 | -- | 1.10x |
|
HLOSF
Healios KK
|
65.07% | -0.707 | 34.39% | 1.33x |
|
PPTDF
PeptiDream
|
25.75% | -2.667 | 6.45% | 3.28x |
|
SNBIF
SanBio
|
-- | -0.161 | -- | -- |
|
TAK
Takeda Pharmaceutical
|
42.19% | 0.312 | 78.44% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SOLTF
Nxera Pharma
|
$48.9M | $5.4M | -2.75% | -5.58% | 11.44% | $10.3M |
|
AMGXF
AnGes
|
$259.5K | -$13M | -37.32% | -22.74% | -1559.14% | -- |
|
HLOSF
Healios KK
|
$2.8M | -$1.8M | -55.94% | -137.21% | -24.5% | -$4.8M |
|
PPTDF
PeptiDream
|
$17.4M | -$854.5K | 24.02% | 34.66% | -1.5% | $173.8M |
|
SNBIF
SanBio
|
-- | -$6.2M | -- | -- | -- | -$10.9M |
|
TAK
Takeda Pharmaceutical
|
$5.3B | $1.8B | 2.37% | 4.01% | 15.97% | $1.3B |
Nxera Pharma vs. Competitors
-
Which has Higher Returns SOLTF or AMGXF?
AnGes has a net margin of 12.96% compared to Nxera Pharma's net margin of -2947.39%. Nxera Pharma's return on equity of -5.58% beat AnGes's return on equity of -22.74%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma78.44% $0.09 $928.9M AMGXFAnGes31.07% -$0.11 $158.3M -
What do Analysts Say About SOLTF or AMGXF?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than AnGes, analysts believe Nxera Pharma is more attractive than AnGes.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 AMGXFAnGes0 0 0 -
Is SOLTF or AMGXF More Risky?
Nxera Pharma has a beta of 0.337, which suggesting that the stock is 66.345% less volatile than S&P 500. In comparison AnGes has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SOLTF or AMGXF?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AnGes offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. AnGes pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or AMGXF?
Nxera Pharma quarterly revenues are $62.4M, which are larger than AnGes quarterly revenues of $835.2K. Nxera Pharma's net income of $8.1M is higher than AnGes's net income of -$24.6M. Notably, Nxera Pharma's price-to-earnings ratio is -- while AnGes's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.79x versus 22.98x for AnGes. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.79x -- $62.4M $8.1M AMGXFAnGes22.98x -- $835.2K -$24.6M
-
Which has Higher Returns SOLTF or HLOSF?
Healios KK has a net margin of 12.96% compared to Nxera Pharma's net margin of -107.23%. Nxera Pharma's return on equity of -5.58% beat Healios KK's return on equity of -137.21%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma78.44% $0.09 $928.9M HLOSFHealios KK86.35% -$0.04 $57.8M -
What do Analysts Say About SOLTF or HLOSF?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than Healios KK, analysts believe Nxera Pharma is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 HLOSFHealios KK0 0 0 -
Is SOLTF or HLOSF More Risky?
Nxera Pharma has a beta of 0.337, which suggesting that the stock is 66.345% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SOLTF or HLOSF?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or HLOSF?
Nxera Pharma quarterly revenues are $62.4M, which are larger than Healios KK quarterly revenues of $3.2M. Nxera Pharma's net income of $8.1M is higher than Healios KK's net income of -$3.4M. Notably, Nxera Pharma's price-to-earnings ratio is -- while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.79x versus 32.00x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.79x -- $62.4M $8.1M HLOSFHealios KK32.00x -- $3.2M -$3.4M
-
Which has Higher Returns SOLTF or PPTDF?
PeptiDream has a net margin of 12.96% compared to Nxera Pharma's net margin of -5.57%. Nxera Pharma's return on equity of -5.58% beat PeptiDream's return on equity of 34.66%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma78.44% $0.09 $928.9M PPTDFPeptiDream47.13% -$0.02 $551.4M -
What do Analysts Say About SOLTF or PPTDF?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than PeptiDream, analysts believe Nxera Pharma is more attractive than PeptiDream.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 PPTDFPeptiDream0 0 0 -
Is SOLTF or PPTDF More Risky?
Nxera Pharma has a beta of 0.337, which suggesting that the stock is 66.345% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.389%.
-
Which is a Better Dividend Stock SOLTF or PPTDF?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or PPTDF?
Nxera Pharma quarterly revenues are $62.4M, which are larger than PeptiDream quarterly revenues of $36.8M. Nxera Pharma's net income of $8.1M is higher than PeptiDream's net income of -$2.1M. Notably, Nxera Pharma's price-to-earnings ratio is -- while PeptiDream's PE ratio is 20.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.79x versus 7.14x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.79x -- $62.4M $8.1M PPTDFPeptiDream7.14x 20.38x $36.8M -$2.1M
-
Which has Higher Returns SOLTF or SNBIF?
SanBio has a net margin of 12.96% compared to Nxera Pharma's net margin of --. Nxera Pharma's return on equity of -5.58% beat SanBio's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma78.44% $0.09 $928.9M SNBIFSanBio-- -$0.08 -- -
What do Analysts Say About SOLTF or SNBIF?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand SanBio has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than SanBio, analysts believe Nxera Pharma is more attractive than SanBio.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 SNBIFSanBio0 0 0 -
Is SOLTF or SNBIF More Risky?
Nxera Pharma has a beta of 0.337, which suggesting that the stock is 66.345% less volatile than S&P 500. In comparison SanBio has a beta of -0.336, suggesting its less volatile than the S&P 500 by 133.637%.
-
Which is a Better Dividend Stock SOLTF or SNBIF?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SanBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. SanBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or SNBIF?
Nxera Pharma quarterly revenues are $62.4M, which are larger than SanBio quarterly revenues of --. Nxera Pharma's net income of $8.1M is higher than SanBio's net income of -$5.8M. Notably, Nxera Pharma's price-to-earnings ratio is -- while SanBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.79x versus 97.52x for SanBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.79x -- $62.4M $8.1M SNBIFSanBio97.52x -- -- -$5.8M
-
Which has Higher Returns SOLTF or TAK?
Takeda Pharmaceutical has a net margin of 12.96% compared to Nxera Pharma's net margin of 7.83%. Nxera Pharma's return on equity of -5.58% beat Takeda Pharmaceutical's return on equity of 4.01%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma78.44% $0.09 $928.9M TAKTakeda Pharmaceutical66.47% $0.19 $83.8B -
What do Analysts Say About SOLTF or TAK?
Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $16.03 which suggests that it could grow by 21.44%. Given that Takeda Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Takeda Pharmaceutical is more attractive than Nxera Pharma.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma0 0 0 TAKTakeda Pharmaceutical3 1 0 -
Is SOLTF or TAK More Risky?
Nxera Pharma has a beta of 0.337, which suggesting that the stock is 66.345% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.209%.
-
Which is a Better Dividend Stock SOLTF or TAK?
Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical offers a yield of 4.72% to investors and pays a quarterly dividend of $0.33 per share. Nxera Pharma pays -- of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or TAK?
Nxera Pharma quarterly revenues are $62.4M, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.9B. Nxera Pharma's net income of $8.1M is lower than Takeda Pharmaceutical's net income of $619.7M. Notably, Nxera Pharma's price-to-earnings ratio is -- while Takeda Pharmaceutical's PE ratio is 21.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.79x versus 1.38x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma2.79x -- $62.4M $8.1M TAKTakeda Pharmaceutical1.38x 21.67x $7.9B $619.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
